Sub lingual immunotherapy of Nasal allergies
Phase 3
- Conditions
- Perennial allergic rhinitis.Other allergic rhinitis
- Registration Number
- IRCT2017042323235N9
- Lead Sponsor
- Vice chancellor for research, Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
approved clinical perennial allergic rhinitis and laboratory diagnosis;the desire of patients to drug treatment and participation in the project
Exclusion criteria: Suffering from seasonal allergic rhinitis, a history of autoimmune disease, Consumption of corticosteroids or immunosuppressive drugs, pregnancy, allergic asthma, malnutrition
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical symptoms of allergic rhinitis. Timepoint: After six month. Method of measurement: questionnaire.
- Secondary Outcome Measures
Name Time Method FOXP3 gene expression. Timepoint: After six month. Method of measurement: Real-Time PCR.;Interlukin-10. Timepoint: After six month. Method of measurement: Real-Time PCR.;Tumor Groeth Factor-B. Timepoint: After six month. Method of measurement: Real-Time PCR.;Interlukin-17. Timepoint: After six month. Method of measurement: Real-Time PCR.